Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Sep 2017 14:31

RNS Number : 0141Q
Destiny Pharma PLC
06 September 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

DESTINY PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

HARGREAVE HALE LIMITED

City and country of registered office (if applicable)

BLACKPOOL, ENGLAND

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

04 SEPTEMBER 2017

6. Date on which issuer notified (DD/MM/YYYY):

06 SEPTEMBER 2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.7092

11.7092

41,651,770

Position of previous notification (if

applicable)

0

0

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BDHSP575

4,877,070

11.7092

SUBTOTAL 8. A

4,877,070

11.7092

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

All of the resulting shares are held in unit trusts operated by Marlborough Fund Managers Ltd, for whom Hargreave Hale Ltd manages the portfolio of investments on a discretionary basis.

 

The change in the percentage of shares held is due mainly to participation in the IPO/placing by Destiny Pharma plc, the shares from which were admitted to AIM on 04/09/2017.

 

Place of completion

HARGREAVE HALE LTD, BLACKPOOL, ENGLAND

Date of completion

06 SEPTEMBER 2017

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEADNKEAPXEFF
Date   Source Headline
28th Mar 20196:13 pmRNSExercise of Options
27th Mar 20197:00 amRNSMedPharm to develop new XF-drug formulations
22nd Mar 20199:47 amRNSNotice of Results
6th Mar 20196:00 pmRNSExercise of Options
28th Jan 20197:00 amRNSSecond positive phase 1 trial data for XF-73
25th Jan 20197:00 amRNSNew grant awarded under UK-China AMR programme
24th Jan 201911:50 amRNSDestiny Pharma notes UK 5-year action plan on AMR
1st Nov 20187:00 amRNSResearch collaboration with Southampton University
25th Oct 20184:05 pmRNSGrant of Options
25th Oct 20187:00 amRNSDirectorate Change
24th Oct 20187:00 amRNSUK government highlights global threat of AMR
19th Oct 20187:00 amRNSBIA celebrates UK bioscience innovative
26th Sep 20187:00 amRNSDr Jesús González appointed Chief Medical Officer
26th Sep 20187:00 amRNSInterim results for six months ended 30 June 2018
6th Sep 20187:00 amRNSDirectorate Change
26th Jul 20187:00 amRNSPositive Phase 1 skin irritation study with XF-73
17th Jul 20187:00 amRNSResearch collaboration with Aston University
11th Jul 20187:00 amRNSNotice of Results
21st Jun 20187:00 amRNSDirectorate Change
14th Jun 20187:00 amRNSDestiny Pharma notes FDA statement on AMR focus
5th Jun 201812:47 pmRNSDirector/PDMR Shareholding
31st May 201812:30 pmRNSResult of AGM
30th May 20187:00 amRNSDestiny Establishes Scientific Advisory Board
23rd Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
12th Apr 20187:00 amRNSDestiny Pharma announces clinical update on XF-73
12th Apr 20187:00 amRNSFinal Results
23rd Mar 20187:00 amRNSNotice of Full Year Results
22nd Mar 20187:00 amRNSAppointment of Joint Broker
15th Mar 20187:00 amRNSFDA Fast Track Designation for lead drug XF-73
26th Feb 20187:00 amRNSDestiny Pharma opens IND ahead of XF-73 US trials
11th Jan 20187:00 amRNSParticipating in Cantor Antibiotics Summit panel
29th Dec 20177:00 amRNSTotal Voting Rights
7th Dec 20179:59 amRNSHolding(s) in Company
1st Dec 20177:01 amRNSChina Medical System Holdings Limited invests £3m
1st Dec 20177:00 amRNSDevelopment and commercial agreement finalised
27th Sep 20177:00 amRNSInterim Results for 6 months ended 30 June 2017
19th Sep 20175:00 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSNotice of Interim Results
6th Sep 20172:31 pmRNSHolding(s) in Company
4th Sep 20177:05 amRNSFramework Agreement with China Medical Systems
4th Sep 20177:00 amRNSAdmission and First Day of Dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.